Sexual inactivity and dyspareunia remained common after cervical radio(chemo)therapy
Sexual inactivity reached 49% and dyspareunia 54% after cervical radio(chemo)therapy, with fatigue central to broader survivorship impairment.
Tag
cervical
DWI/ADC changed residual cervical tumor geometry before brachytherapy despite similar overall volumes
Adding DWI/ADC produced substantially different residual GTV geometry before cervical brachytherapy, with a median Dice overlap of only 0.33.
Multimodal AI predicted radiation proctitis across different CT devices with 0.865 AUC
Combined radiomics, foundation-model and clinical features predicted grade ≥2 radiation proctitis with 0.865 AUC on an independent imaging device.
Cervical cancer advanced by one stage approximately every 8.6 weeks before radiotherapy
Cervical cancer stage progression was estimated every 8.6 weeks of treatment delay and was faster among women living with HIV.
Low CAVIN3 expression was associated with better radiotherapy response in cervical cancer
Low CAVIN3 expression was associated with higher treatment response and substantially longer progression-free survival after radiotherapy for cervical cancer.
Task-specific deep learning reduced CT metal artifacts in cervical brachytherapy
Task-specific deep learning halved pelvic artifact burden, improved applicator reconstruction to 0.1 mm, and shortened organ contouring by up to 40%.
On Ethos, intensity-modulated radiotherapy generated faster and spared several pelvic organs better than arc therapy
Nine-field intensity-modulated radiotherapy shortened overall planning-plus-delivery time and improved several pelvic dose metrics compared with volumetric modulated arc therapy.
Daily adaptation supported 17-fraction definitive chemoradiotherapy for cervical cancer
Daily online adaptation improved pelvic target coverage during 17-fraction cervical chemoradiotherapy, with 10% grade ≥3 gastrointestinal toxicity.
Retroverted uterus altered cervical brachytherapy dosimetry without worsening disease control
Retroverted uterine position increased rectal and bowel dose during cervical brachytherapy, but survival, recurrence and severe toxicity remained comparable.
Patient-specific 3D-printed templates enabled efficient brachytherapy for complex cervical cancer
Template-guided implantation achieved a median HR-CTV D90 of 92.9 Gy with low severe toxicity across 555 brachytherapy fractions.
PocketNet matched nnU-Net segmentation with 40-fold lower model storage
PocketNet matched nnU-Net accuracy for cervical MRI segmentation while using 40-fold less storage and approximately half the training time.
A 55-gene hypoxia signature identified poor-prognosis cervical cancer across cohorts
A 55-gene hypoxia classifier independently predicted worse survival and retained prognostic value across Manchester, Seoul, and Norwegian cervical cancer cohorts.
Iodine-125 brachytherapy achieved short-term control in previously irradiated cervical nodal metastases
Iodine-125 seed implantation produced 90% three-month disease control, but median local progression-free survival was nine months.
Higher pretreatment LMR weakly predicted cervical tumour shrinkage after EBRT
Pretreatment lymphocyte-to-monocyte ratio was independently associated with cervical tumour shrinkage, but its standalone discrimination was poor.
EQD2 remains essential but uncertain in modern cervical HDR brachytherapy
EQD2 should remain the reporting standard, but delivery time, dose gradients, biological assumptions and dose accumulation materially affect its interpretation.